- Home
- ORIQ vs IMUX Comparison
ORIQ vs IMUX Comparison
Compare ORIQ & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORIQ | IMUX |
|---|---|---|
| Founded | 2024 | 2016 |
| Country | | |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.0M | 75.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ORIQ | IMUX |
|---|---|---|
| Price | $10.20 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 37.5K | ★ 5.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.98 | $0.51 |
| 52 Week High | $10.22 | $1.39 |
Technical Indicators
Market Signals| Indicator | ORIQ | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 58.85 | 69.78 |
| Support Level | $10.16 | $0.68 |
| Resistance Level | $10.20 | $1.20 |
| Average True Range (ATR) | 0.01 | 0.10 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 75.00 | 51.46 |
Price Performance
Historical ComparisonAbout ORIQ Origin Investment Corp I Ordinary Shares
Origin Investment Corp I is a blank check company.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.